Savella generic release date?

When Will Savella's Patent Expire, and Who Will Make the Generic Version?

Savella, also known as milnacipran, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat fibromyalgia and depression. [1] As of now, the patent for Savella is still in force, and the exact generic release date can be difficult to pinpoint due to frequent patent extensions and the complexities of the pharmaceutical regulatory landscape.

Why Is the Patent for Savella Being Challenged?

Several pharmaceutical companies have challenged the patent for Savella, which could potentially lead to the development and release of generic versions of the medication. However, it's crucial to note that the regulatory process for generic drugs is lengthy and involves demonstrating bioequivalence to the brand name version.

Who Makes Generic Versions of Savella?

DrugPatentWatch.com [2] provides a list of generic companies that have filed for approval to produce milnacipran. Some notable players in the pharmaceutical industry that may have an interest in producing generic Savella include:

- Mylan Inc.
- Hikma Pharmaceuticals
- Sandoz (Novartis)

Please note that this list is subject to change and may not reflect the current market situation.

How Does the Generic Release Date Affect You?

When the patent for Savella expires, generic versions of the medication will become available, which could lead to increased competition and potentially lower prices. However, this might not necessarily result in a dramatic price drop.

According to Drugs.com [3], the prices of generic milnacipran may still be similar to the brand version due to various factors such as marketing costs, clinical trials, and patent litigation.

Sources:

1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. Drugs.com

References:

[1] Savella - FDA Approved Drug Details. DrugPatentWatch.com
[2] Milnacipran Generic Approval. DrugPatentWatch.com
[3] Milnacipran (Savella) - RxList. Drugs.com